CAL-02 by Eagle Pharmaceuticals for Community-Acquired Bacterial Pneumonia: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CAL-02 overview
CAL-02 (combioxin) is under development for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections, Pseudomonas aeruginosa infections, hepatitis C infections, severe community-acquired pneumonia caused by Streptococcus pneumoniae. It is administered through intravenous route. The drug candidate comprises empty, uni-lamellar, uncoated, neutral, small liposomes composed of cholesterol and sphingomyelin and of sphingomyelin only. It acts as a decoy by mimicking microdomains targeted by diverse bacterial toxins.
It was also under development for the treatment of gram-negative bacterial infections.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Eagle Pharmaceuticals overview
Eagle Pharmaceuticals (Eagle) is a specialty pharmaceutical company that offers proprietary pharmaceutical injectables in the therapy areas of critical care, oncology, and various orphan diseases. The company’s key commercial products encompass pharmaceutical injectables, including Ryanodex for exertional heatstroke; Bendeka, and Belrapzo, both for the treatment of chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL). Pipeline products of the company include EP-4104 (dantrolene sodium) for exertional heat stroke (EHS) and nerve agent exposure; EA-114 (fulvestrant) for the treatment of breast cancer and Vasopressin injection for blood pressure. The company’s products cater to patients and healthcare professionals in the areas of critical care, orphan diseases, and oncology. Eagle Pharmaceuticals is headquartered in Woodcliff Lake, New Jersey, the US.
For a complete picture of CAL-02’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#CAL02 #Eagle #Pharmaceuticals #CommunityAcquired #Bacterial #Pneumonia #Likelihood #Approval
